Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Some people may report fewer side effects after switching to a different GLP-1
Based on these Phase 1 results, the company initiated a 13 Week Phase 2 trial with the oral formulation of VK2735 in obesity in January 2025
The benefits beyond weight loss are substantial and growing as more research emerges
McMurray JJV, Solomon SD, Inzucchi SE, Kber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Blohlvek J, Bhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukt A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, OMeara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjstrand M, Langkilde A-M
Other medications, including liraglutide (Saxenda) and tirzepatide (Zepbound), can also lead to weight loss and lower blood pressure
